Alnylam Pharma (ALNY) Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
Go back to Alnylam Pharma (ALNY) Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 143.80 -2.27 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.07 | 52 Week High | $109.10 | |||
| Open | $146.60 | 52 Week Low | $31.38 | |||
| Day High | $147.49 | P/E | N/A | |||
| Day Low | $143.52 | EPS | $-1.45 | |||
| Volume | 395,369 | |||||
